Breakthrough Pill Nearly Doubles Survival Time For One of The Deadliest Cancers

Experimental pill daraxonrasib nearly doubled survival for previously treated metastatic pancreatic cancer, extending median life to 13.2 months versus 6.7 months with chemotherapy.

The KRAS-pathway drug also caused fewer severe side effects and improved pain and quality of life in the study of about 500 patients.

Researchers say the results could make daraxonrasib a new standard option for this hard-to-treat cancer.

Experts are urging expanded access and faster FDA review as the drug moves closer to approval.